K36 Therapeutics translate epigenetic modulation of oncogenic pathways into small molecule therapies.
K36 Therapeutics has raised $70.0M in total funding. The most recent round was Series B. The last funding was announced in June 2023.
K36 Therapeutics's investors include Eight Roads Ventures, Atlas Venture, F-Prime, Bristol-Myers Squibb, Nextech Invest.
K36 Therapeutics is headquartered in Cambridge, United States.
K36 Therapeutics translate epigenetic modulation of oncogenic pathways into small molecule therapies.
K36 Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"K36 Therapeutics — Funding & Investors." VCBacked, June 28, 2023, https://www.vcbacked.co/company/k36-therapeutics. Accessed August 13, 2026.
VCBacked. (2023). K36 Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/k36-therapeutics
{{cite web |title=K36 Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/k36-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated